Stockscreener 앱 받기
13.12
4.02%
-0.55
Carlsmed Inc 주식(CARL)의 최신 뉴스
Earnings Preview: Carlsmed to Report Financial Results Post-market on August 28 - 富途牛牛
People moves: Michael Kaplan rejoins StandardAero as legal chief as Jenifer Kamocsay moves over to Carlsmed - | Governance Intelligence
Carlsmed names Jennifer Kamocsay as CLO and secretary - Medical Buyer
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary - Orthopedics This Week
Carlsmed appoints Jenifer Kamocsay as chief legal officer By Investing.com - Investing.com Nigeria
Carlsmed appoints Jennifer Kamocsay as CLO, secretary - TipRanks
Carlsmed appoints Jenifer Kamocsay as chief legal officer - Investing.com India
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary - GlobeNewswire Inc.
Carlsmed, Inc. Selected for Inclusion in Russell 2000 Index - 富途牛牛
Carlsmed joins Russell 2000 Index following Q3 IPO - MSN
Carlsmed announces inclusion in Russell 2000 Index - TipRanks
Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index - MarketScreener
AI-Powered Spine Surgery Innovator Carlsmed Joins $9T Russell 2000 Index Following Successful IPO - Stock Titan
AI medtech firm Carlsmed prices $100.5M IPO - MSN
AI medtech firm Carlsmed to sell 6.7M shares in IPO - MSN
Goldman Sachs highlights two high-potential stocks: AI marketing platform Braze (BRZE.US) and medical technology company Carlsmed (CARL.US), assigning them a 'Buy' rating. - 富途牛牛
Carlsmed initiated with Buy at Truist on business potential - MSN
Carlsmed Q2 2025 revenue up 99% to USD 12.1M - Medical Buyer
Carlsmed stock rating reiterated at Buy by Goldman Sachs on growth outlook - Investing.com Australia
Carlsmed, Inc.: Strong Financial Performance and Growth Potential Justify Buy Rating - TipRanks
Carlsmed, Inc.: Strong Performance and Promising Growth Prospects with Upcoming Product Launch - TipRanks
UPDATECarlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Carlsmed Reports Strong Growth in Q2 2025 Earnings - TipRanks
Carlsmed 2025 Q2 Earnings Strong Revenue Growth Despite Widening Net Loss - AInvest
Carlsmed: A High-Growth AI-Driven MedTech Play in Spine Surgery - AInvest
Earnings call transcript: Carlsmed’s Q2 2025 revenue surges, stock rises - Investing.com
Carlsmed Q2 Loss Narrows, Revenue Rises - MarketScreener
Carlsmed reports second quarter 2025 financial results - MarketScreener
Carlsmed® Q2 2025 Financial Performance: Assessing Long-Term Growth Potential in the AI-Driven Spine Surgery Revolution - AInvest
CARLSMED, INC. SEC 10-Q Report - TradingView
Carlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Carlsmed, Inc.'s Q2 2025 Performance and Strategic Momentum: A Disruptive Force in AI-Driven Spine Surgery - AInvest
99% Growth: AI Spine Surgery Pioneer Carlsmed Hits $12.1M Revenue, Expands into Cervical Procedures - Stock Titan
Carlsmed CARL 2025Q2 Earnings Preview Upside Potential on AI-Driven Spine Solutions - AInvest
Two AI Small Caps Nobody Noticed - Nanalyze
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Truist Securities initiates coverage on Carlsmed stock with Buy rating By Investing.com - Investing.com Australia
Why Is Carlsmed Stock Gaining Monday?Carlsmed (NASDAQ:CARL) - Benzinga
Truist Initiates Buy on Carlsmed with Focus on Business Growth Potential - AInvest
Carlsmed initiated with Buy at Truist on business potential (CARL) - Seeking Alpha
BofA Securities Initiates Coverage on Carlsmed With Buy Rating, $16 Price Target - MarketScreener
This Synaptics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Goldman Sachs Initiates Coverage on Carlsmed With Buy Rating, $19 Price Target - MarketScreener
Carlsmed initiated with a Buy at BTIG - TipRanks
Truist Securities initiates coverage on Carlsmed stock with Buy rating - Investing.com
Truist Initiates Carlsmed at Buy With $18 Price Target - MarketScreener
Piper Sandler initiates coverage on Carlsmed with an Overweight rating, PT of $18. - AInvest
Buy Rating for Carlsmed: Innovative Aprevo Technology and Strong Growth Projections Justify Premium Valuation - TipRanks
Carlsmed stock initiated with Buy rating at BTIG on customized implant tech - Investing.com
8.35%
1.76%
자본화:
|
볼륨(24시간):